Clinical Trial Update: A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Participants With Familial Chylomicronemia Syndrome (FCS) [Phase 3]

View source ↗

Summary

A Phase 3 trial update for olezarsen (AKCEA-APOCIII-LRx) in Familial Chylomicronemia Syndrome indicates the study is active but not currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Familial Chylomicronemia Syndrome

Drugs mentioned

• Olezarsen (olezarsen)

Snippet

Sponsor: Ionis Pharmaceuticals, Inc. | Conditions: Familial Chylomicronemia Syndrome | Phase 3 | Status: ACTIVE_NOT_RECRUITING